Pharmacological inhibition of Lp-PLA2 is most effective in reducing risk of major coronary events for patients with T2DM and high Lp-PLA2 activity, resulting in a 33% reduction in the risk of major coronary events [36]. This evidence concerns the gene PLA2G7 and type 2 diabetes mellitus.